23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › ZENTALIS PHARMACEUTICALS INC. › 2023-2024

ZENTALIS PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ZENTALIS PHARMACEUTICALS INC.’s Form 8-K, filed June 21, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 149Asset managers, any item
  • 1,009Fund votes
  • June 21, 2024Meeting date

Results at a glance

Meeting of June 21, 2024: 4 items on ZENTALIS PHARMACEUTICALS INC.’s Form 8-K, filed June 21, 2024: 1 approved · 3 passed (calculated).

Dissent

Significant dissent: 2 directors (26.1%, 21.0% against); 1 say-on-pay vote (59.4% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ZENTALIS PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by ZENTALIS PHARMACEUTICALS INC.

These tallies are ZENTALIS PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 21, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ZENTALIS PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 21, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Kimberly Blackwell, M.D. 48,055,584---- 12,810,3705,241,491 79%Passed (calculated)—
Elect Director: Enoch Kariuki, Pharm.D. 45,008,378---- 15,857,5765,241,491 74%Passed (calculated)—
2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 66,098,0835,6653,697 --0 99.9%Passed (calculated)—
3. Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers 36,128,13024,729,7308,094 --5,241,491 59%Approved—

Source: ZENTALIS PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 21, 2024 — read the filing on EDGAR.

How asset managers voted at the ZENTALIS PHARMACEUTICALS INC. 2023-2024 meeting

149 asset managers disclosed a vote on at least one ZENTALIS PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Enoch Kariuki, Pharm.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 45,008,378WITHHELD: 15,857,576
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Enoch Kariuki, Pharm.D.

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Enoch Kariuki, Pharm.D.”): 45,008,378 for, 15,857,576 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 26,053,408 for, 3,793 against, 8,053,220 withheld, 74,983 abstained.

FORWITHHOLD
FOR: 26,053,408AGAINST: 3,793ABSTAIN: 74,983WITHHOLD: 8,053,220
Largest asset managers voting on “Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respecti” at ZENTALIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST11,557,4220 00For
Fidelity641,0760 05,807,130Mixed
Vanguard4,242,9380 00For
T. Rowe Price2,724,7690 01,423,364Mixed
Capital Group2,819,6640 00For
Federated Hermes1,731,8000 00For
PRIMECAP Odyssey Funds850,2500 00For
BlackRock661,0190 00For
Charles Schwab457,1960 00For
State Street2550 0244,906Withhold
Equitable109,0450 056,518Mixed
Direxion Shares ETF Trust00 0158,906Withhold
John Hancock52,1980 31,4850Mixed
TIAA00 080,808Withhold
ProShares00 059,364Withhold
Lincoln Financial00 055,570Withhold
Northwestern Mutual00 042,509Withhold
Brighthouse24,8590 012,629Mixed
SEI32,5400 00For
QUANTITATIVE MASTER SERIES LLC29,4530 00For
Thrivent00 027,707Withhold
Global X26,5450 00For
Voya19,2430 00For
Pacific Life18,8870 00For
JPMorgan00 18,4780Abstain

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Elect Director: Kimberly Blackwell, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 48,055,584WITHHELD: 12,810,370
Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respective successors shall have been duly elected and qualified, subject to their earlier death, resignation or removal: Kimberly Blackwell, M.D.

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Kimberly Blackwell, M.D.”): 48,055,584 for, 12,810,370 withheld, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 27,984,776 for, 3,793 against, 6,149,913 withheld, 46,922 abstained.

FORWITHHOLD
FOR: 27,984,776AGAINST: 3,793ABSTAIN: 46,922WITHHOLD: 6,149,913
Largest asset managers voting on “Election of Class I Directors to serve until the 2027 Annual Meeting of Stockholders, and until their respecti” at ZENTALIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST11,557,4220 00For
Fidelity641,0760 05,807,130Mixed
Vanguard4,242,9380 00For
T. Rowe Price4,148,1330 00For
Capital Group2,819,6640 00For
Federated Hermes1,731,8000 00For
PRIMECAP Odyssey Funds850,2500 00For
BlackRock661,0190 00For
Charles Schwab457,1960 00For
State Street244,8310 0330For
Equitable165,5630 00For
Direxion Shares ETF Trust00 0158,906Withhold
John Hancock61,7810 21,9020Mixed
TIAA80,8080 00For
ProShares00 059,364Withhold
Lincoln Financial49,5000 06,070Mixed
Northwestern Mutual42,5090 00For
Brighthouse24,8590 012,629Mixed
SEI32,5400 00For
QUANTITATIVE MASTER SERIES LLC29,4530 00For
Thrivent00 027,707Withhold
Global X26,5450 00For
Voya19,2430 00For
Pacific Life18,8870 00For
JPMorgan18,4780 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

59% Approved · of votes cast

FOR 59%AGAINST
FOR: 36,128,130AGAINST: 24,729,730

Prior year: 35.3% for (June 16, 2023 meeting) ▲ 24.1 pts

Details: description as filed, official tally, votes by 149 asset managers

Description as filed by funds: To approve, on an advisory (non- binding) basis, the compensation of our named executive officers.

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“3. Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers”): 36,128,130 for, 24,729,730 against — passed, per its Form 8-K filed June 21, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Item 3 — Approval, on an advisory (non-binding) basis, the compensation of the Company's named executive officers.”
Support: 59% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 58 asset managers voting on “To approve, on an advisory (non- binding) basis, the compensation of our named executive officers.” at ZENTALIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST11,557,4220 00For
Fidelity24,4016,423,805 00Against
Vanguard4,242,9380 00For
T. Rowe Price04,148,133 00Against
Capital Group02,819,664 00Against
Federated Hermes1,731,8000 00For
PRIMECAP Odyssey Funds0850,250 00Against
BlackRock661,0190 00For
Charles Schwab0457,196 00Against
State Street255244,906 00Against
Equitable90,14075,423 00Mixed
Direxion Shares ETF Trust0158,906 00Against
John Hancock083,683 00Against
TIAA80,8080 00For
ProShares059,364 00Against
Lincoln Financial055,570 00Against
Northwestern Mutual042,509 00Against
Brighthouse037,488 00Against
SEI032,540 00Against
QUANTITATIVE MASTER SERIES LLC29,4530 00For
Thrivent027,707 00Against
Global X026,545 00Against
Voya019,243 00Against
Pacific Life18,8870 00For
JPMorgan018,478 00Against

Fund voting reports, all 58 managers: 18,456,490 for, 15,723,823 against, 1,298 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 113 asset managers voting on “To approve, on an advisory (non- binding) basis, the compensation of our named executive officers.” at ZENTALIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Matrix Capital Management Company, LP11,545,7570 00For
Fidelity07,814,905 00Against
T. Rowe Price06,199,571 00Against
Decheng Capital LLC3,070,4420 00For
Capital Group02,819,664 00Against
Federated Hermes1,731,8000 00For
MPM BioImpact LLC1,526,5930 00For
BlackRock1,490,7538,201 00For
PRIMECAP MANAGEMENT CO/CA/01,141,610 00Against
Verition Fund Management LLC01,079,807 00Against
TYBOURNE CAPITAL MANAGEMENT (HK) LTD0961,486 00Against
State Street255850,310 00Against
GEODE CAPITAL MANAGEMENT, LLC0708,586 00Against
Paradigm Biocapital Advisors LP0669,336 00Against
Citadel513,7970 00For
5AM Venture Management, LLC488,5900 00For
Charles Schwab0457,196 00Against
Boxer Capital, LLC450,0000 00For
Northern Trust0299,617 00Against
Rafferty Asset Management, LLC0158,906 00Against
Allianz0125,380 00Against
MELLON INVESTMENTS Corp093,330 00Against
Two Sigma086,704 00Against
Nuveen82,9460 00For
JPMorgan081,790 00Against

Institutional-manager reports, all 113 managers: 21,118,097 for, 24,192,707 against. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 66,098,083AGAINST: 5,665

Prior year: 100.0% for (June 16, 2023 meeting) unchanged

Details: description as filed, official tally, votes by 59 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.

ZENTALIS PHARMACEUTICALS INC.’s own tally for this item (“2. Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 66,098,083 for, 5,665 against, per its Form 8-K filed June 21, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 59 asset managers below reported 34,184,106 for, 1,298 abstained.

FOR
FOR: 34,184,106ABSTAIN: 1,298
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fi” at ZENTALIS PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
MUTUAL FUND SERIES TRUST11,557,4220 00For
Fidelity6,448,2060 00For
Vanguard4,242,9380 00For
T. Rowe Price4,148,1330 00For
Capital Group2,819,6640 00For
Federated Hermes1,731,8000 00For
PRIMECAP Odyssey Funds850,2500 00For
BlackRock661,0190 00For
Charles Schwab457,1960 00For
State Street245,1610 00For
Equitable165,5630 00For
Direxion Shares ETF Trust158,9060 00For
John Hancock83,6830 00For
TIAA80,8080 00For
ProShares59,3640 00For
Lincoln Financial55,5700 00For
Northwestern Mutual42,5090 00For
Brighthouse37,4880 00For
SEI32,5400 00For
QUANTITATIVE MASTER SERIES LLC29,4530 00For
Thrivent27,7070 00For
Global X26,5450 00For
Voya19,2430 00For
Pacific Life18,8870 00For
JPMorgan18,4780 00For

Showing the 25 largest of 59 asset managers. All 59 are in the interactive database (link above).

Largest ZENTALIS PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 71,013,233 shares outstanding at the time of that meeting.

Fund voting reports: top ZENTALIS PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory (non- binding) basis, the compensation of our named executive…”, 2023-2024
#Asset manager % of shares outstanding
1MUTUAL FUND SERIES TRUST 16.28%
2Fidelity 9.08%
3Vanguard 5.97%
4T. Rowe Price 5.84%
5Capital Group 3.97%
6Federated Hermes 2.44%
7PRIMECAP Odyssey Funds 1.20%
8BlackRock 0.93%
9Charles Schwab 0.64%
10State Street 0.35%
Institutional-manager reports: top ZENTALIS PHARMACEUTICALS INC. shareholders by shares voted on “To approve, on an advisory (non- binding) basis, the compensation of our named executive…”, 2023-2024
#Asset manager % of shares outstanding
1Matrix Capital Management Company, LP 16.26%
2Fidelity 11.00%
3T. Rowe Price 8.73%
4Decheng Capital LLC 4.32%
5Capital Group 3.97%
6Federated Hermes 2.44%
7MPM BioImpact LLC 2.15%
8BlackRock 2.11%
9PRIMECAP MANAGEMENT CO/CA/ 1.61%
10Verition Fund Management LLC 1.52%

Reported ZENTALIS PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

ZENTALIS PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Matrix Capital Management Master Fund, LP13,959,973 19.66%Proxy statement (DEF 14A), proxy filed April 29, 2024
Eventide Asset Management, LLC11,559,975 16.28%Proxy statement (DEF 14A), proxy filed April 29, 2024
FMR LLC10,336,971 14.56%Proxy statement (DEF 14A), proxy filed April 29, 2024
Citadel Advisors3,880,129 5.46%Form 13F, quarter ended March 31, 2024
State Street3,785,652 5.33%Form 13F, quarter ended March 31, 2024
T. Rowe Price3,489,709 4.91%Form 13F, quarter ended March 31, 2024
Vanguard Group2,904,400 4.09%Form 13F, quarter ended March 31, 2024
Morgan Stanley1,407,829 1.98%Form 13F, quarter ended March 31, 2024
Kimberly Blackwell, M.D.1,355,283 1.91%Proxy statement (DEF 14A), proxy filed April 29, 2024
BlackRock1,249,504 1.76%Form 13F, quarter ended March 31, 2024

Percentages above are of 71,013,233 shares outstanding, as reported by ZENTALIS PHARMACEUTICALS INC. on its Form 10-Q dated May 3, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At ZENTALIS PHARMACEUTICALS INC.'s shareholder meeting held June 21, 2024, in the 2023-2024 proxy season, 149 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,009 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory (non- binding) basis, the compensation of our named executive… — ZENTALIS PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 59% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ZENTALIS PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 21, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ZENTALIS PHARMACEUTICALS INC.’s 10-Q dated May 3, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

ZENTALIS PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “ZENTALIS PHARMACEUTICALS (ZNTL) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/zentalis-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.